ā
AI-generated deep summary
by claude@2026-07, 2026-07-17
Ā· read from full text
ā
The study investigated how morphine modulates pain-related neural dynamics in the anterior cingulate cortex, using mice with nerve injury to model chronic neuropathic pain. Across longitudinal neural recordings and deep-learning behavioral analysis, the authors identified a persistent post-injury shift in cortical activity patterns associated with an affective, unpleasant chronic pain state, and found that morphine reversed these neuropathic cortical dynamics and reduced affective-motivational behaviors without changing sensory detection or reflexive responses. They further engineered a biologically inspired gene therapy using a synthetic mu-opioid receptor promoter to target opioid-sensitive cingulate neurons and used chemogenetic inhibition to recapitulate morphine-like analgesic effects with on-demand control. The paper notes patent involvement related to the custom constructs, which is a stated limitation for disclosure and potential bias considerations. The paper does not explicitly discuss endometriosis or adenomyosis; it was included in the corpus via a keyword match in the upstream search index.
Abstract
The anterior cingulate cortex is a key brain region involved in the affective and motivational dimensions of pain, yet how opioid analgesics modulate this cortical circuit remains unclear. Uncovering how opioids alter nociceptive neural dynamics to produce pain relief is essential for developing safer and more targeted treatments for chronic pain. Here we show that a population of cingulate neurons encodes spontaneous pain-related behaviors and is selectively modulated by morphine. Using deep-learning behavioral analyses combined with longitudinal neural recordings in mice, we identified a persistent shift in cortical activity patterns following nerve injury that reflects the emergence of an unpleasant, affective chronic pain state. Morphine reversed these neuropathic neural dynamics and reduced affective-motivational behaviors without altering sensory detection or reflexive responses, mirroring how opioids alleviate pain unpleasantness in humans. Leveraging these findings, we built a biologically inspired gene therapy that targets opioid-sensitive neurons in the cingulate using a synthetic mu-opioid receptor promoter to drive chemogenetic inhibition. This opioid-mimetic gene therapy recapitulated the analgesic effects of morphine during chronic neuropathic pain, thereby offering a new strategy for precision pain management targeting a key nociceptive cortical opioid circuit with safe, on-demand analgesia. Abstract Figure
Full text
2,847 characters
Ā· extracted from
oa-doi-fallback
Ā· click to expand
Abstract
The anterior cingulate cortex is a key brain region involved in the affective and motivational dimensions of pain, yet how opioid analgesics modulate this cortical circuit remains unclear. Uncovering how opioids alter nociceptive neural dynamics to produce pain relief is essential for developing safer and more targeted treatments for chronic pain. Here we show that a population of cingulate neurons encodes spontaneous pain-related behaviors and is selectively modulated by morphine. Using deep-learning behavioral analyses combined with longitudinal neural recordings in mice, we identified a persistent shift in cortical activity patterns following nerve injury that reflects the emergence of an unpleasant, affective chronic pain state. Morphine reversed these neuropathic neural dynamics and reduced affective-motivational behaviors without altering sensory detection or reflexive responses, mirroring how opioids alleviate pain unpleasantness in humans. Leveraging these findings, we built a biologically inspired gene therapy that targets opioid-sensitive neurons in the cingulate using a synthetic mu-opioid receptor promoter to drive chemogenetic inhibition. This opioid-mimetic gene therapy recapitulated the analgesic effects of morphine during chronic neuropathic pain, thereby offering a new strategy for precision pain management targeting a key nociceptive cortical opioid circuit with safe, on-demand analgesia.
Competing Interest Statement
G.C, K.D., C.R. and G.J.S. are inventors on a provisional patent application through the University of Pennsylvania and Stanford University regarding the custom sequences used to develop, and the applications of mMORp and hMORp constructs (patent application number: 63/383,462 462: Human and Murine Oprm1 Promotes and Uses Thereof).
Footnotes
āµā Co-First Authors
āµ* Co-Senior Authors
-Structural refinement across the Introduction to Discussion to emphasize the conceptual significance of cortical gene therapy for chronic pain. -Condensed the Main Figures from 5 to 4, and the Supplementary Figures from 31 to 18. -Focused data presentation by removing or relocating peripheral elements and replication data (e.g., evoked pain measures, opioid cell-type FISH and single nuclei RNAseq) to the Supplement. -Enhanced visualization, with simplified figures, standardized metrics (e.g., LUPE-based deep-learning modeling for spontaneous pain behaviors), and new schematics to clearly convey each figure message. -Expanded methods and figure legends to ensure reproducibility. -New experiments, including: o Calcium imaging with synchronized LUPE tracking across chronic pain development (Figure 3). o A Mouse Pain Scale to quantify analgesia and test our gene therapy (All figures). o Imaging of single-neuron responses to pain and appetitive/aversive stimuli (Supp. Figs. 11 - 12).
Text is read by the "Ask this paper" AI Q&A widget below.
Extraction quality varies by source ā PMC NXML preserves structure
cleanly, OA-HTML may include some navigation residue, and OA-PDF can
have broken hyphenation. The publisher copy
(via DOI)
is the canonical version.